Advance Auto Parts beats Q3 expectations, raises full-year guidance, and sees strong operational improvements.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Controversy erupts over proposed appointment of Yair Netanyahu to senior WZO board position, disrupting negotiations and unity efforts.
Advance Auto Parts beats Q3 expectations, raises full-year guidance, and sees strong operational improvements.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Controversy erupts over proposed appointment of Yair Netanyahu to senior WZO board position, disrupting negotiations and unity efforts.